Pharmaceutical Business review

InVitria Completes Beta Testing Of Optiferrin For Mammalian Cell Culture

InVitria has launched Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth by regulating the amount of iron transported to the cell.

Optiferrin addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, Hybridoma Cells and Chinese Hamster Ovary (CHO) cells.

Scott Deeter, president and CEO of InVitria, said: “Optiferrin has undergone extensive testing by our beta customers since June 2009. They have formulated Optiferrin into their cell culture media to provide maximum performance and they liked their results. We are delighted to be able to bring this sort of value to our customers through innovations like Optiferrin,”

Steve Pettit, director of cell culture development at InVitria, said: “Transferrin is nature’s way to deliver iron in a non-toxic manner. Our product development, along with beta customer results, confirmed that Optiferrin delivered optimal performance without any cell damage. This alleviates customer’s concerns about animal-origin infectious contaminants or the headaches caused by addition of elemental iron and iron chelators in cell culture media.”